中国医学创新Issue(35)：35-37,3.DOI:10.3969/j.issn.1674-4985.2015.35.011
三氧化二砷介入治疗中晚期原发性肝癌的临床疗效研究
Study on the Clinical Effects of Arsenic Trioxide in the Treatment of Advanced Primary Liver Cancer by ;Interventional Ways
摘要
Abstract
Objective:To study the clinical effects,adverse reactions and safety of Arsenic Trioxide in interventional treatment of advanced primary liver cancer. Method:156 patients with primary liver cancer in our hospital from March 2013 to February 2015 were selected and randomly divided into two groups,each group had 78 cases. All patients received the interventional treatment.The observation group was treated with Arsenic Trioxide 20 mg, Mitomycin 10 mg,Lobapatin 50 mg and UFL 10 mL.The control group was treated with Epirubicin 40 mg/m2, Mitomycin 10 mg,Lobapatin 50 mg and UFL 10 mL.The treatment effect,adverse reactions and living quality of the two groups were compared.Result:The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant(P<0.05).During treatment,the major adverse reactions were bone marrow suppression,nausea and vomiting,pain,fever,hepatic injury and so on. The symptoms were effectively relieved after taking measures.There were neitherⅣdegree toxic response nor death related to the treatment.After treatment,the improvement of quality of life in the observation group was more obvious.Conclusion:The interventional treatment of Arsenic Trioxide in advanced primary liver cancer can improve the total efficiency,promote patients’quality of life and has fewer adverse reactions. Arsenic Trioxide is a better choice for hepatocarcinoma interventional therapy,which is worthy of clinical promotion.关键词
原发性肝癌/介入治疗/三氧化二砷/临床疗效/安全性Key words
Primary hepatic carcinoma/Interventional treatment/Arsenic Trioxide/Clinical effect/Safety引用本文复制引用
邱从坤,汤日杰,王忠富,侯毅斌,周志鹏,陈国硕..三氧化二砷介入治疗中晚期原发性肝癌的临床疗效研究[J].中国医学创新,2015,(35):35-37,3.基金项目
广东省自然科学基金项目 （）
